Medicine and Dentistry
Ion Therapy
92%
Neoplasm
50%
Radiation Therapy
39%
Neck
22%
Relative Biologic Effectiveness
21%
Overall Survival
21%
Non Small Cell Lung Cancer
20%
Survival Rate
19%
Lung Cancer
19%
Adverse Event
16%
Cervical Cancer
16%
Treatment Planning
14%
Squamous Cell Carcinoma
12%
Recurrent Disease
12%
Disease
12%
Brain Metastasis
11%
Head and Neck Tumor
11%
Radiation Oncology
11%
Computer Assisted Tomography
10%
Mucositis
10%
Dose-Volume Histogram
9%
Observational Study
9%
Chemotherapy
9%
MALT Lymphoma
9%
Brachytherapy
8%
Progression Free Survival
8%
Mucosal Melanoma
8%
Drug Megadose
8%
Stereotactic Body Radiation Therapy
7%
High-Dose-Rate Brachytherapy
7%
External Beam Radiotherapy
7%
Lung
7%
Malignant Neoplasm
7%
Intensity Modulated Radiation Therapy
7%
Rectum Cancer
7%
Cylindroma
6%
Retrospective Study
6%
Chemoradiotherapy
6%
Metastatic Carcinoma
6%
Prospective Study
5%
Single Drug Dose
5%
Carcinoma
5%
Magnetic Resonance Imaging
5%
Adenocarcinoma
5%
Cyberknife
5%
Prostate Cancer
5%
Stereotactic Radiotherapy
5%
Bone Tissue
5%
Keyphrases
Carbon Ion Radiotherapy
100%
Tumor
28%
Head-and-neck
21%
Radiation Therapy
17%
Non-small Cell Lung Cancer (NSCLC)
15%
Relative Biological Effectiveness
15%
Overall Survival Rate
15%
Japan
15%
Local Control
14%
Stage I Lung Cancer
14%
Radiotherapy
13%
Treatment Planning
12%
Neck Tumor
11%
HDR Brachytherapy
11%
Oncology Studies
10%
Radiation Oncology
10%
Local Control Rate
10%
Clinical Outcomes
10%
Total Dose
10%
Non-squamous Cell Carcinoma
10%
Apoptosis
9%
Uterine Cervical Cancer
9%
Lung Cancer
9%
Prospective Observational Study
9%
Brain Metastases
9%
MALT Lymphoma
9%
Irradiation
8%
Dose-volume Histogram
8%
Locally Advanced
8%
Hypofractionation
8%
Dose Distribution
8%
Brachytherapy
8%
Radiosensitivity
8%
External Beam Radiotherapy
8%
Concurrent Chemoradiotherapy
7%
Stereotactic Body Radiotherapy
7%
Retrospective multicenter Study
7%
Hyperthermia
7%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
7%
Overall Survival
7%
Chemotherapy
7%
Mucositis
6%
Progression-free Survival
6%
Mucosal Melanoma
6%
Adenoid Cystic Carcinoma
6%
Local Recurrence
6%
Hypoxia-inducible factor-1α (HIF-1α)
6%
Late Toxicity
6%
Group Studies
6%
Phase II Study
6%